Mesa Labs Appoints Siddhartha Kadia as New CEO
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 09 2026
0mins
Should l Buy MLAB?
Mesa Labs announced that Gary Owens will step down as president and CEO on April 12 and will enable a leadership transition. To lead the company's next chapter, the board of directors has appointed Siddhartha Kadia as president and CEO, effective April 13. Kadia will also join the board. Kadia most recently served as CEO of Calibre Scientific.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MLAB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MLAB
Wall Street analysts forecast MLAB stock price to rise
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 81.130
Low
83.00
Averages
99.00
High
115.00
Current: 81.130
Low
83.00
Averages
99.00
High
115.00
About MLAB
Mesa Laboratories, Inc. designs and manufactures life sciences tools and critical control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. The Company's segments include Sterilization and Disinfection Control, Clinical Genomics, Biopharmaceutical Development, and Calibration Solutions. Sterilization and Disinfection Control segment manufactures and sells biological, chemical and cleaning indicators. Clinical Genomics segment develops, manufactures and sells genetic analysis tools and related consumables and services. Biopharmaceutical Development segment develops, manufactures, sells and services automated systems for protein analysis and peptide synthesis solutions. Calibration Solutions segment develops, manufactures, sells and services control products using principles of advanced metrology to enable customers to measure and calibrate critical parameters in applications, such as renal care, environmental and process monitoring.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
MLAB Stock 52-Week High and Low Analysis
- Price Fluctuation Analysis: MLAB's 52-week low is $55.45 per share, while the high is $131.20, with the last trade at $82.00, indicating significant volatility in its stock price over the past year, reflecting varying market expectations about its future performance.
- Market Trend Observation: The current stock price of $82.00 is above the 52-week low, suggesting a partial recovery of investor confidence; however, it remains significantly below the high, which may indicate a cautious market sentiment regarding its growth potential.
- Technical Indicator Reference: MLAB's stock price has crossed above the 200-day moving average, potentially attracting more technical analysis investors, which could further drive the stock price upward and enhance market activity.
- Investor Sentiment Assessment: Although the current stock price is positioned in the middle of the 52-week range, market views on MLAB remain divided, necessitating close monitoring of upcoming earnings reports and market dynamics for informed decision-making.
See More
U.S. Stocks Mixed in Morning Trading
- Dow Jones Decline: On Tuesday, the Dow Jones fell approximately 0.07% to 47,709.07 points after market opening, reflecting cautious sentiment towards economic data that may impact investor confidence.
- NASDAQ Gains: In contrast, the NASDAQ rose by 0.13% to 22,724.49 points, indicating a relatively strong performance in tech stocks, which could attract more capital inflows into this sector.
- United Natural Foods' Mixed Results: Shares of United Natural Foods, Inc. (NYSE:UNFI) dropped around 7% on Tuesday, as its quarterly earnings of 62 cents per share exceeded the analyst consensus of 51 cents, yet its sales of $7.947 billion fell short of the $8.108 billion estimate, highlighting market challenges.
- Commodity Market Fluctuations: Oil prices fell by 8% to $87.24, while gold increased by 2.3% to $5,221.20, reflecting heightened demand for safe-haven assets, which may also impact the profitability of related companies.
See More
Mesa Laboratories CEO Transition and Earnings Beat Expectations
- Executive Transition: Mesa Laboratories' president and CEO Gary Owens will step down on April 12, 2026, with Siddhartha Kadia appointed as his successor effective April 13, 2026, indicating a strategic leadership shift to align with future growth objectives.
- New CEO Background: Prior to this role, Siddhartha Kadia served as CEO of Calibre Scientific, and his extensive industry experience is expected to bring fresh perspectives and leadership to Mesa Laboratories, potentially driving further innovation in the medical device sector.
- Earnings Highlights: Mesa Laboratories reported a GAAP EPS of $0.65, beating expectations by $0.37, while revenue reached $65.13 million, exceeding forecasts by $1.9 million, showcasing the company's strong market performance and profitability.
- Market Reaction: The earnings beat is likely to boost investor confidence in Mesa Laboratories, potentially driving its stock price higher and providing a solid foundation for the incoming CEO's tenure.
See More
Mesa Laboratories Appoints New CEO
- Leadership Transition: Mesa Laboratories announced that current CEO Gary Owens will step down on April 12, 2026, marking a significant leadership change that is expected to impact the company's strategic direction and market performance.
- New CEO Background: Dr. Siddhartha Kadia will take over as CEO on April 13, 2026, bringing extensive management experience in life sciences from his previous roles at Calibre Scientific and PhenomeX, which is anticipated to drive Mesa's market expansion and technological innovation.
- Board Support: Board Chair John Sullivan stated that Kadia's leadership skills and experience in technology commercialization will provide strong support for Mesa's next phase of development, reflecting the company's confidence in future growth.
- Company Vision: Kadia expressed his eagerness to work with the team to build on Mesa's strong foundation and continue delivering long-term value, emphasizing the company's leadership in life science tools and critical quality control solutions.
See More
Mesa Laboratories Q4 Earnings Exceed Expectations
- Earnings Highlights: Mesa Laboratories reported a Q4 GAAP EPS of $0.65, beating expectations by $0.37, indicating a significant enhancement in profitability and reflecting the company's strengthened competitive position in the market.
- Revenue Growth: The company achieved Q4 revenue of $65.13 million, a 3.6% year-over-year increase, surpassing market expectations by $1.9 million, demonstrating sustained demand and steady market share growth in the medical device sector.
- Core Business Performance: On a non-GAAP basis, core organic revenue growth was 1.2%, while adjusted operating income (AOI) increased by 17.6% to $17.072 million, further solidifying the company's profitability within the industry.
- Excluding Unusual Items: Excluding CG China revenues, the non-GAAP organic revenue growth rate was 5.7%, showcasing Mesa Laboratories' robust performance in global markets, particularly in the diagnostics sector's ongoing expansion.
See More
Mesa Laboratories Declares $0.16 Quarterly Dividend Per Share
- Quarterly Dividend Announcement: Mesa Laboratories has declared a quarterly dividend of $0.16 per share of common stock, payable on March 16, 2026, which aims to reward shareholders and enhance investor confidence.
- Shareholder Record Date: The dividend will be distributed to shareholders of record at the close of business on February 28, 2026, ensuring eligible shareholders receive their returns promptly, thereby strengthening the company's relationship with investors.
- Company Background: Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for the pharmaceutical, healthcare, and medical device industries, dedicated to improving product integrity and safety.
- Forward-Looking Statements: The company cautions investors about the risks and uncertainties associated with forward-looking statements, emphasizing that actual results may differ significantly from expectations, ensuring transparency and compliance.
See More
MLAB Stock 52-Week High and Low Analysis
- Price Fluctuation Analysis: MLAB's 52-week low is $55.45 per share, while the high is $131.20, with the last trade at $82.00, indicating significant volatility in its stock price over the past year, reflecting varying market expectations about its future performance.
- Market Trend Observation: The current stock price of $82.00 is above the 52-week low, suggesting a partial recovery of investor confidence; however, it remains significantly below the high, which may indicate a cautious market sentiment regarding its growth potential.
- Technical Indicator Reference: MLAB's stock price has crossed above the 200-day moving average, potentially attracting more technical analysis investors, which could further drive the stock price upward and enhance market activity.
- Investor Sentiment Assessment: Although the current stock price is positioned in the middle of the 52-week range, market views on MLAB remain divided, necessitating close monitoring of upcoming earnings reports and market dynamics for informed decision-making.
See More
U.S. Stocks Mixed in Morning Trading
- Dow Jones Decline: On Tuesday, the Dow Jones fell approximately 0.07% to 47,709.07 points after market opening, reflecting cautious sentiment towards economic data that may impact investor confidence.
- NASDAQ Gains: In contrast, the NASDAQ rose by 0.13% to 22,724.49 points, indicating a relatively strong performance in tech stocks, which could attract more capital inflows into this sector.
- United Natural Foods' Mixed Results: Shares of United Natural Foods, Inc. (NYSE:UNFI) dropped around 7% on Tuesday, as its quarterly earnings of 62 cents per share exceeded the analyst consensus of 51 cents, yet its sales of $7.947 billion fell short of the $8.108 billion estimate, highlighting market challenges.
- Commodity Market Fluctuations: Oil prices fell by 8% to $87.24, while gold increased by 2.3% to $5,221.20, reflecting heightened demand for safe-haven assets, which may also impact the profitability of related companies.
See More
Mesa Laboratories CEO Transition and Earnings Beat Expectations
- Executive Transition: Mesa Laboratories' president and CEO Gary Owens will step down on April 12, 2026, with Siddhartha Kadia appointed as his successor effective April 13, 2026, indicating a strategic leadership shift to align with future growth objectives.
- New CEO Background: Prior to this role, Siddhartha Kadia served as CEO of Calibre Scientific, and his extensive industry experience is expected to bring fresh perspectives and leadership to Mesa Laboratories, potentially driving further innovation in the medical device sector.
- Earnings Highlights: Mesa Laboratories reported a GAAP EPS of $0.65, beating expectations by $0.37, while revenue reached $65.13 million, exceeding forecasts by $1.9 million, showcasing the company's strong market performance and profitability.
- Market Reaction: The earnings beat is likely to boost investor confidence in Mesa Laboratories, potentially driving its stock price higher and providing a solid foundation for the incoming CEO's tenure.
See More
Mesa Laboratories Appoints New CEO
- Leadership Transition: Mesa Laboratories announced that current CEO Gary Owens will step down on April 12, 2026, marking a significant leadership change that is expected to impact the company's strategic direction and market performance.
- New CEO Background: Dr. Siddhartha Kadia will take over as CEO on April 13, 2026, bringing extensive management experience in life sciences from his previous roles at Calibre Scientific and PhenomeX, which is anticipated to drive Mesa's market expansion and technological innovation.
- Board Support: Board Chair John Sullivan stated that Kadia's leadership skills and experience in technology commercialization will provide strong support for Mesa's next phase of development, reflecting the company's confidence in future growth.
- Company Vision: Kadia expressed his eagerness to work with the team to build on Mesa's strong foundation and continue delivering long-term value, emphasizing the company's leadership in life science tools and critical quality control solutions.
See More
Mesa Laboratories Q4 Earnings Exceed Expectations
- Earnings Highlights: Mesa Laboratories reported a Q4 GAAP EPS of $0.65, beating expectations by $0.37, indicating a significant enhancement in profitability and reflecting the company's strengthened competitive position in the market.
- Revenue Growth: The company achieved Q4 revenue of $65.13 million, a 3.6% year-over-year increase, surpassing market expectations by $1.9 million, demonstrating sustained demand and steady market share growth in the medical device sector.
- Core Business Performance: On a non-GAAP basis, core organic revenue growth was 1.2%, while adjusted operating income (AOI) increased by 17.6% to $17.072 million, further solidifying the company's profitability within the industry.
- Excluding Unusual Items: Excluding CG China revenues, the non-GAAP organic revenue growth rate was 5.7%, showcasing Mesa Laboratories' robust performance in global markets, particularly in the diagnostics sector's ongoing expansion.
See More
Mesa Laboratories Declares $0.16 Quarterly Dividend Per Share
- Quarterly Dividend Announcement: Mesa Laboratories has declared a quarterly dividend of $0.16 per share of common stock, payable on March 16, 2026, which aims to reward shareholders and enhance investor confidence.
- Shareholder Record Date: The dividend will be distributed to shareholders of record at the close of business on February 28, 2026, ensuring eligible shareholders receive their returns promptly, thereby strengthening the company's relationship with investors.
- Company Background: Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for the pharmaceutical, healthcare, and medical device industries, dedicated to improving product integrity and safety.
- Forward-Looking Statements: The company cautions investors about the risks and uncertainties associated with forward-looking statements, emphasizing that actual results may differ significantly from expectations, ensuring transparency and compliance.
See More
